Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Lumiliximab (DHC21301)

Host species:Chimeric
Isotype:IgG1-kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHC21301

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Chimeric

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

Lymphocyte IgE receptor, C-type lectin domain family 4 member J, Low affinity immunoglobulin epsilon Fc receptor, CD23A, BLAST-2, Immunoglobulin E-binding factor, IGEBF, CD23, Fc-epsilon-RII, CLEC4J, FCE2, FCER2

Concentration

1.66 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P06734

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

IDEC-152, P5E8, CAS: 357613-86-6

Clone ID

Lumiliximab

Data Image
  • SDS-PAGE
    SDS PAGE for Lumiliximab
References

Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects, PMID: 16210051

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia, PMID: 19843887

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines, PMID: 18032710

Anti-CD23, PMID: 16222084

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia, PMID: 25130401

Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia, PMID: 17671129

Technology evaluation: lumiliximab, Biogen Idec, PMID: 15663332

Novel Drugs in Follicular Lymphoma, PMID: 27872741

Refractory chronic lymphocytic leukemia--new therapeutic strategies, PMID: 21317446

Treatment of relapsed or refractory chronic lymphocytic leukemia, PMID: 22143061

Monoclonal antibodies in chronic lymphocytic leukemia, PMID: 17020457

Antibody therapy for chronic lymphocytic leukemia, PMID: 18381104

Monoclonal antibody therapy of chronic lymphocytic leukemia, PMID: 16187090

Newer monoclonal antibodies for hematological malignancies, PMID: 18565392

State-of-the-art treatment of chronic lymphocytic leukemia, PMID: 20008230

Targeted therapy for chronic lymphocytic leukemia, PMID: 19343298

Standard of care and novel treatments for chronic lymphocytic leukemia, PMID: 20966144

Modern concepts in the treatment of chronic lymphocytic leukemia, PMID: 19843378

Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia, PMID: 18336199

Gateways to clinical trials, PMID: 18985183

Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art, PMID: 25249370

Novel antibodies in the treatment of non-Hodgkin's lymphoma, PMID: 19767657

Gateways to clinical trials, PMID: 21225019

Novel agents for the treatment of chronic lymphocytic leukemia, PMID: 21326166

The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia, PMID: 23667725

Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia, PMID: 19562616

Current and emerging treatments for chronic lymphocytic leukaemia, PMID: 19911856

Isolation of human Fab antibodies specific for the low-affinity IgE receptor (CD23) by selecting a hierarchical antibody library system against B lymphoblastic IM-9 cells, PMID: 21277901

Phase behavior of an intact monoclonal antibody, PMID: 17449660

Datasheet

Document Download

Research Grade Lumiliximab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Lumiliximab [DHC21301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only